Neurofilament light chain: a biomarker for genetic frontotemporal dementia

Annals of Clinical and Translational Neurology

Volumn 3, Issue 8, 2016, Pages 623-636

  Meeter, Lieke H ^a   Dopper, Elise G ^a   Jiskoot, Lize C ^a   Sanchez Valle, Raquel ^b   Graff, Caroline ^c,d   Benussi, Luisa ^e   Ghidoni, Roberta ^e   Pijnenburg, Yolande A ^f   Borroni, Barbara ^g   Galimberti, Daniela ^h   Laforce, Robert Jr ⁱ   Masellis, Mario ^j,k   Vandenberghe, Rik ^l,m   Ber, Isabelle Le ^n,o   Otto, Markus ^p   van Minkelen, Rick ^a   Papma, Janne M ^a   Rombouts, Serge A ^q,r   Balasa, Mircea ^b   Öijerstedt, Linn ^c,d   Jelic, Vesna ^c,d   Dick, Katrina M ^s   Cash, David M ^c,t   Harding, Sophie R ^s   Jorge Cardoso, M ^s,t   Ourselin, Sebastien ^t   Rossor, Martin N ^s   Padovani, Alessandro ^g   Scarpini, Elio ^h   Fenoglio, Chiara ^h   Tartaglia, Maria C ^o   Lamari, Foudil ^u   Barro, Christian ^v   Kuhle, Jens ^v   Rohrer, Jonathan D ^s   Teunissen, Charlotte E ^w   van Swieten, John C ^a,w   more..

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b HOSPITAL CLÍNIC   (Spain)

^c KAROLINSKA INSTITUTE   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g UNIVERSITY OF BRESCIA   (Italy)

^h UNIVERSITY OF MILAN   (Italy)

ⁱ LAVAL UNIVERSITY   (Canada)

^j SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^k Canada   (Canada)

^l UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^m UNIVERSITY OF LEUVEN   (Belgium)

ⁿ SORBONNE UNIVERSITÉ   (France)

^o PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^p UNIVERSITY OF ULM   (Germany)

^q LEIDEN UNIVERSITY   (Netherlands)

^r LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^s UNIVERSITY COLLEGE LONDON   (United Kingdom)

^t UNIVERSITY COLLEGE LONDON   (United Kingdom)

^u UNIVERSITY OF TORONTO   (Canada)

^v UNIVERSITY HOSPITAL BASEL   (Switzerland)

^w VU UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; NEUROFILAMENT PROTEIN; PROGRANULIN; TAU PROTEIN;

ADULT; AGED; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL DEMENTIA RATING; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE DURATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FRONTOTEMPORAL DEMENTIA; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN READING FRAME; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SURVIVAL;

EID: 85018393902     PISSN: None     EISSN: 23289503     Source Type: Journal    
DOI: 10.1002/acn3.325     Document Type: Article

References (42)

1. Seelaar H, Rohrer JD, Pijnenburg YAL, et al. Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. J Neurol Neurosurg Psychiatry 2011;82:476–486.
2. Baker M, Mackenzie IR, Pickering-Brown SM, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 2006;442:916–919.
3. Hutton M, Lendon CL, Rizzu P, et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998;393:702–705.
4. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011;72:245–256.
5. Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011;72:257–268.
6. Rohrer JD, Nicholas JM, Cash DM, et al. Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. Lancet Neurol 2015;4422:1–10.
7. Dopper EGP, Rombouts SA, Jiskoot LC, et al. Structural and functional brain connectivity in presymptomatic familial frontotemporal dementia. Neurology 2014;83:e19–e26.
8. Bateman RJ, Xiong C, Benzinger TLS, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012;367:795–804.
9. Tabrizi SJ, Scahill RI, Owen G, et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol 2013;12:637–649.
10. Scherling CS, Hall T, Berisha F, et al. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann Neurol 2014;75:116–126.
11. Skillback T, Farahmand B, Bartlett JW, et al. CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. Neurology 2014;83:1945–1953.
12. Steinacker P, Feneberg E, Weishaupt J, et al. Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry 2016;87:12–20.
13. Zetterberg H, Skillbäck T, Mattsson N, et al. Association of cerebrospinal fluid neurofilament light concentration with alzheimer disease progression. JAMA Neurol 2016;73:60–67.
14. Kuhle J, Disanto G, Lorscheider J, et al. Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis. Neurology 2015;84:1639–1643.
15. Weydt P, Oeckl P, Huss A, et al. Neurofilaments levels as biomarkers in asymptomatic and symptomatic familial ALS. Ann Neurol 2015;DOI:10.1002/ana.24552.
16. Petzold A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci 2005;233:183–198.
17. Yuan A, Sershen H, Veeranna A, et al. Neurofilament subunits are integral components of synapses and modulate neurotransmission and behavior in vivo. Mol Psychiatry 2015;20:989–994.
18. Lu C-H, Macdonald-Wallis C, Gray E, et al. Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology 2015;84:2247–2257.
19. Genetic FTD Initiative [Internet]. Available at: http://genfi.org.uk/ (accessed November 2015)
20. Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011;134:2456–2477.
21. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998;51:1546–1554.
22. Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology 2011;76:1006–1014.
23. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
24. Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology 1993;43:2412–2414.
25. Benussi L, Ghidoni R, Pegoiani E, et al. Progranulin Leu271LeufsX10 is one of the most common FTLD and CBS associated mutations worldwide. Neurobiol Dis 2009;33:379–385.
26. Brooks BR, Miller RG, Swash M, Munsat TL.El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:293–299.
27. Modat M, Ridgway GR, Taylor ZA, et al. Fast free-form deformation using graphics processing units. Comput Methods Programs Biomed 2010;98:278–284.
28. Cardoso MJ, Modat M, Wolz R, et al. Geodesic information flows: spatially-variant graphs and their application to segmentation and fusion. IEEE Trans Med Imaging 2015;34:1976–1988.
29. BrainCOLOR Protocol [Internet]. Available at: http://braincolor.mindboggle.info/docs/BrainCOLOR_cortical_parcellation_protocol.pdf (accessed November 2015).
30. Neuromorphometrics [Internet]. Available at: http://www.neuromorphometrics.org:8080/seg/ (accessed November 2015).
31. Gaiottino J, Norgren N, Dobson R, et al. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS One 2013;8:1–9.
32. Limberg M, Disanto G, Barro C, Kuhle J. Neurofilament light chain determination from peripheral blood samples. Methods Mol Biol 2016;1304:93–98.
33. Youden WJ. Index for rating diagnostic tests. Cancer 1950;3:32–35.
34. Landqvist Waldö M, Frizell Santillo A, Passant U, et al. Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia. BMC Neurol 2013;13:54.
35. Caroppo P, Le Ber I, Camuzat A, et al. Extensive white matter involvement in patients with frontotemporal lobar degeneration. JAMA Neurol 2014;71:1562.
36. Sjögren M, Blomberg M, Jonsson M, et al. Neurofilament protein in cerebrospinal fluid: a marker of white matter changes. J Neurosci Res 2001;66:510–516.
37. Menke RAL, Gray E, Lu C-H, et al. CSF neurofilament light chain reflects corticospinal tract degeneration in ALS. Ann Clin Transl Neurol 2015;2:748–755.
38. Whitwell JL, Weigand SD, Boeve BF, et al. Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. Brain 2012;135:794–806.
39. Whitwell JL, Boeve BF, Weigand SD, et al. Brain atrophy over time in genetic and sporadic frontotemporal dementia: a study of 198 serial magnetic resonance images. Eur J Neurol 2015;22:745–752.
40. Benatar M, Wuu J. Presymptomatic studies in ALS: rationale, challenges, and approach. Neurology 2012;79:1732–1739.
41. Petzold A, Altintas A, Andreoni L, et al. Neurofilament ELISA validation. J Immunol Methods 2010;352:23–31.
42. Koel-Simmelink MJA, Vennegoor A, Killestein J, et al. The impact of pre-analytical variables on the stability of neurofilament proteins in CSF, determined by a novel validated SinglePlex Luminex assay and ELISA. J Immunol Methods 2014;402:43–49.